Minocycline (free base)

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 413027

CAS#: 10118-90-8 (free base)

Description: Minocycline (free base) is A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.


Chemical Structure

img
Minocycline (free base)
CAS# 10118-90-8 (free base)

Theoretical Analysis

MedKoo Cat#: 413027
Name: Minocycline (free base)
CAS#: 10118-90-8 (free base)
Chemical Formula: C23H27N3O7
Exact Mass: 457.1849
Molecular Weight: 457.48
Elemental Analysis: C, 60.39; H, 5.95; N, 9.19; O, 24.48

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 13614-98-7 (HCl)   10118-90-8 (free base)  

Synonym: Minocycline (free base), HSDB3130; HSDB-3130; HSDB 3130

IUPAC/Chemical Name: 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-

InChi Key: DYKFCLLONBREIL-KVUCHLLUSA-N

InChi Code: InChI=1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27,29-30,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1

SMILES Code: O=C(C(C1=O)=C(O)[C@@H](N(C)C)[C@]2([H])C[C@]3([H])CC4=C(C(C3=C(O)[C@@]21O)=O)C(O)=CC=C4N(C)C)N

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 457.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Garner SE, Eady A, Bennett C, Newton JN, Thomas K, Popescu CM. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2012 Aug 15;2012(8):CD002086. doi: 10.1002/14651858.CD002086.pub2. PMID: 22895927; PMCID: PMC7017847.

2: Rosenblat JD, McIntyre RS. Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials. J Affect Disord. 2018 Feb;227:219-225. doi: 10.1016/j.jad.2017.10.042. Epub 2017 Oct 28. PMID: 29102836.

3: Jonas M, Cunha BA. Minocycline. Ther Drug Monit. 1982;4(2):137-45. PMID: 7048646.

4: Allen JC. Minocycline. Ann Intern Med. 1976 Oct;85(4):482-7. doi: 10.7326/0003-4819-85-4-482. PMID: 788583.

5: Minocycline foam (Amzeeq) for acne. Med Lett Drugs Ther. 2020 May 4;62(1597):68-70. PMID: 32555112.

6: Zheng W, Zhu XM, Zhang QE, Cheng G, Cai DB, He J, Ng CH, Ungvari GS, Peng XJ, Ning YP, Xiang YT. Adjunctive minocycline for major mental disorders: A systematic review. J Psychopharmacol. 2019 Oct;33(10):1215-1226. doi: 10.1177/0269881119858286. Epub 2019 Jul 11. PMID: 31294649.

7: Haghi-Aminjan H, Asghari MH, Goharbari MH, Abdollahi M. A systematic review on potential mechanisms of minocycline in kidney diseases. Pharmacol Rep. 2017 Aug;69(4):602-609. doi: 10.1016/j.pharep.2017.02.001. Epub 2017 Feb 8. PMID: 28500967.

8: Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav Brain Res. 2009 Jan 23;196(2):168-79. doi: 10.1016/j.bbr.2008.09.040. Epub 2008 Oct 11. PMID: 18977395.

9: Nagarakanti S, Bishburg E. Is Minocycline an Antiviral Agent? A Review of Current Literature. Basic Clin Pharmacol Toxicol. 2016 Jan;118(1):4-8. doi: 10.1111/bcpt.12444. Epub 2015 Aug 2. PMID: 26177421.

10: Ochsendorf F. Minocycline in acne vulgaris: benefits and risks. Am J Clin Dermatol. 2010;11(5):327-41. doi: 10.2165/11319280-000000000-00000. PMID: 20642295.